The BalancedInvestor Club

AYTU Market Analysis

Overview

Fundamentals

P/E ratio—Forward 3.69
EPS (TTM)$-3.440.0% YoY
Profit margin-39.0%HEALTHCARE
Market cap$28.0MMicro cap

Wall Street coverage

$9.33median target· current $3.06 (+204.9%)3 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
3.69
PEG ratio
0.00
P/B
1.98
P/S (TTM)
0.45
EV/EBITDA
1.14

Profitability & growth

ROE (TTM)
-109.2%
Operating margin
-13.0%
Revenue growth YoY
-6.5%
Dividend yield
—
Beta
0.28
Last earnings
Feb 4, 2026 · Estimate $-0.50 · Reported $-0.23
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Aytu BioScience Inc

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and marketing novel products in the field of hypogonadism (low testosterone levels), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company is headquartered in Englewood, Colorado.

Classification

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
DENVER CORPORATE CENTER III, DENVER, CO
Fiscal year end
June
Latest quarter
Dec 31, 2025
Market cap$28.0M
Shares outstanding$10.7M
52W high$3.07
52W low$1.20

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer